Final Programme - iuphar

More documents

Recommendations

Info

FC07 Simulation and data modelling in drug development. Better drugs faster? Tue 190 Infliximab pharmacokinetics in rheumatoid arthritis is influenced by body surface area, erythrocyte sedimentation rate, methotrexate and antibodies towards infliximab Gilles Paintaud, (France), E Ducourau, T David, C Anca, LG Benoît, P Aleth, D Valérie, S-G Elisabeth, G Philippe, M Denis Tue 191 Pharmacokinetics of florfenicol following a single SC injection in calves Ali Rassouli, (Iran), P Lees, P Sidhu Tue 192 New approach for fitting of data of fluorescence anisotropy and intensity for characterization of ligand binding to melanocortin 4 receptors Ago Rinken, (Estonia), S Veiksina, S Kopanchuk Tue 193 α2 adrenoceptor distribution in pig brain, mapped with radiolabeled yohimbine by means of positron emission tomography A Rodell, S Jakobsen, Albert Gjedde, (Denmark) Tue 194 Design of novel and selective HDAC8-inhibitors as anticancer agents Barij Nayan Sinha, (India), V Jayaprakash Tue 195 7TM-homology modelling of long form of human and rat D2 dopamine receptor and validation for evaluating ligands recognition Marvin A Soriano-Ursúa, (Mexico), JO Ocampo-López, JG Trujillo-Ferrara, J Correa-Basurto Tue 196 The RAAS hypertension PhysioLab platform: A systems modelling approach to hypertension Antoine Soubret, (Switzerland), A Sarkar, M Hallow, B Bieth, A Georgieva, A Lo, J Beh, S Ermakov, S Ramanujan, M Rodrigo, D Keefe, A Charney Tue 197 Influence of non-compliance on antimicrobial therapy with levofloxacin based on pharmacokinetic/ pharmacodynamic simulation Maria Elena Suarez Gonzalez, (Spain), N Carral, R Calvo Duo, J Lukas Tue 198 Methotrexate influences neither pharmacokinetics nor concentration-effect relationship of infliximab in ankylosing spondylitis David Ternant, (France), F Lauferon, D Mulleman, D Wendling, E Ducourau, J-P Valat, P Goupille, G Paintaud 214 Tuesday 20 July ■ 13:00 - 14:00 ■ Poster Area
FC08 Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract Tue 199 Regulation of urothelial spontaneous contractile activity Christian Moro, (Australia), R Chess-Williams Tue 200 The relationship between hyperlipidemia-induced erectile dysfunction and serum ADMA levels in a time dependent manner N Murat, A Toylu, Atiye Sinem Evcim, (Turkey), BC Soner, O Demir, B Irer, T Demir, N Atabey, S Gidener, AA Esen Tue 201 Alteration of carbachol-induced prostate contraction in adiponectin transgenic mice Koji Nobe, (Japan), A Fujii, T Negoro, K Saito, Y Nakano, T Hashimoto, K Honda Tue 202 The effect of testosterone on intracellular calcium and cAMP in human cultured prostatic stromal cells Victoria Oliver, (Australia), C Anderson, J Haynes Tue 203 Comparison of the effects of AdTx1 and tamsulosin on the increase in intra-urethral and arterial pressures induced by phenylephrine in anesthetized male rats Stefano Palea, (France), N Gilles, V Guilloteau, M Guérard, P Lluel Tue 204 Stimulation of β3-adrenoceptors inhibits EFS-induced contractions of human isolated urinary bladder M Rekik, C Rouget, P Camparo, H Botto, P Lluel, T Westfall, Stefano Palea, (France) Tue 205 Involvement of both β2- and β3-adrenoceptors in the inhibition of neurogenic contractions of mouse isolated urinary bladder C Rouget, T Westfall, M Rekik, P Lluel, Stefano Palea (France) Tue 206 Stimulation of both both β2- and β3-adrenoceptors produces relaxation of KCl-induced contractions of mouse isolated urinary bladder C Rouget, T Westfall, M Rekik, P Lluel, Stefano Palea, (France) Tue 207 Effect of psychotropic drugs (Fluoxetine and Mirtazapine) on Phenylephrine-induced rat vas deferens contractility Cristina Sampayo, (Portugal), I Silva, R Pinto, B Silva-Lima Tue 208 Interaction between nitric oxide and dopaminergic transmission in the peripheral control of penile erection Amira Senbel, (Egypt) Tue 209 Acute toxicity studies and phytochemical screening of an erectile dysfunction herbal treatment; Kosteletzskya begoniifolia (Ulbr) Julius Kihdzee Tanayen, (Uganda), J Oloro, AA Ganafa Tue 210 Expression of phosphodiesterase (PDE) isoenzymes PDE4, PDE5 and PDE11 in the human seminal vesicles – an immunohistochemical study Stefan Ückert, (Germany), J Sonnenberg, V Steffenhagen, M Kuczyk, P Hedlund Tue 211 Is there a significance of the cyclic AMP specific phosphodiesterase 4 (PDE4) in the control of prostate smooth muscle? A functional and biochemical approach Stefan Ückert, (Germany), D Schönfeld, G Kedia, M Kuczyk Tue 212 Rho-kinase related proteins in human vaginal arteries – functional and immunohistochemical studies Stefan Ückert, (Germany), E Waldkirch, M Kuczyk, P Hedlund Tue 213 Impaired Ca 2+ handling in penile arteries from prediabetic Zucker rats: Involvement of Rho-kinase N Villalba, A García-Sacristán, M Hernández, Dolores Prieto, (Spain) Tuesday 20 July ■ 13:00 - 14:00 ■ Poster Area 215
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
W02 Symposium on advances in GI pha
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
Page 66 and 67:
FC03 Ion channels in analgesia and
Page 68 and 69:
FC05 Translational science in the m
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
FC09 Inflammation and immunopharmac
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
FC02 Transmembrane transport: Persp
Page 86 and 87:
FC04 Pharmacoepidemiology, current
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
FC12 Ion channelopathies: New windo
Page 144 and 145:
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
Page 164 and 165:
Page 166 and 167: FC02 Transmembrane transport: Persp
Page 168 and 169: FC03 Ion channels in analgesia and
Page 170 and 171: W12 Experimental pain methods in de
Page 172 and 173: FC04 Pharmacoepidemiology, current
Page 174 and 175: FC05 Translational science in the m
Page 178 and 179: FC06 The heart gone wrong; stabiliz
Page 180 and 181: FC07 Simulation and data modelling
Page 182 and 183: FC08 Developments in the treatment
Page 184 and 185: FC09 Inflammation and immunopharmac
Page 190 and 191: FC13 Maximising benefits and minimi
Page 194 and 195: W03 Targeting TRP channels for pain
Page 196 and 197: W19 Influence of degeneration and r
Page 198 and 199: W19 Influence of degeneration and r
Page 200 and 201: W20 Pharmacology education for a su
Page 202 and 203: FC01 Clinical pharmacology in the e
Page 208 and 209: FC04 Pharmacoepidemiology, current
Page 214 and 215: FC06 The heart gone wrong; stabiliz
Page 218 and 219: FC08 Developments in the treatment
Page 230 and 231: FC19 General session Tue 361 Analge
Page 232 and 233: FC19 General session - Biologics Tu
Page 234 and 235: FC19 General session - Haematology
Page 236 and 237: FC19 General session - oncology Tue
Page 238 and 239: FC19 General session - oncology Tue
Page 240 and 241: FC19 General session - Toxicology T
Page 242 and 243: W02 Symposium on advances in GI pha
Page 244 and 245: W11 New opportunities in the pharma
Page 246 and 247: W23 Applying pharmacogenomics (PGX)
Page 248 and 249: FC10 Drugs for half the world: Paed
Page 250 and 251: FC11 G protein-coupled 7TM receptor
Page 252 and 253: FC11 G protein-coupled 7TM receptor
Page 254 and 255: FC12 Ion channelopathies: New windo
Page 260 and 261: FC14 Addiction and doping: Neurobio
Page 262 and 263: FC15 Endothelium in health and dise
Page 264 and 265: FC15 Endothelium in health and dise
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?